Reuters: Regulatory News: UPDATE 1-Chelsea Therapeutics' rheumatoid arthritis drug fails trial

Reuters: Regulatory News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

UPDATE 1-Chelsea Therapeutics' rheumatoid arthritis drug fails trial May 31st 2012, 12:18 Thu May 31, 2012 8:18am EDT May 31 (Reuters) - Chelsea Therapeutics International Ltd said it will stop developing its experimental drug for rheumatoid arthritis after the treatment failed a mid-stage study, sending its shares down 27 percent before the bell. The drugmaker said methotrexate, the standard treatment for rheumatoid arthritis, showed better results than its drug CH-4051 in the trial. "The outcome of the trial was confounded by the unexpectedly robust response reported by patients treated with methotrexate," Chelsea Therapeutics CEO Simon Pedder said. The Charlotte, North Carolina-based company will now focus on the development of its hypotension drug Northera. The company is facing shareholder lawsuits after the U.S. health regulators declined to give marketing approval to Northera in its current form. Chelsea Therapeutics shares, which have lost about 47 percent of their value since the Northera application was turned down, closed at $1.95 on Wednesday on Nasdaq. They fell to $1.42 in trading before the bell on Thursday.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions